Paper

Interferon receptor gene dosage determines diverse hallmarks of Down syndrome

Rachubinski, Angela L., Britton, Eleanor C., Minter, Ross, Lyford, Hannah R., Orlicky, David J., Matsuda, Jennifer L., Song, Kunhua, Sullivan, Kelly D., Tuttle, Kathryn D., Tracy, Dayna, Anderson, Ryan D., Andrysik, Zdenek, Busquet, Nicolas, Estrada, Belinda Enriquez, Galbraith, Matthew D., Smith, Keith P., Eduthan, Neetha P., Granrath, Ross E., Kinning, Kohl T., Dunn, Lauren N., Ludwig, Michael, Waugh, Katherine A., Cox, Liza L., Chi, Congwu, Baxter, Jessica, Dougherty, Hannah, Araya, Paula, Espinosa, Joaquin M., Schade, Kyndal A., Khanal, Santosh, Cox, Timothy C.

2022

Overview

Trisomy 21 causes Down syndrome, a condition characterized by cognitive impairments, immune dysregulation, and atypical morphogenesis. Using whole blood transcriptome analysis, we demonstrate that specific overexpression of four interferon receptors encoded on chromosome 21 associates with chronic interferon hyperactivity and systemic inflammation in Down syndrome. To define the contribution of interferon receptor overexpression to Down syndrome phenotypes, we used genome editing to correct interferon receptor gene dosage in mice carrying triplication of a large genomic region orthologous to human chromosome 21. Normalization of interferon receptor copy number attenuated lethal antiviral responses, prevented heart malformations, decreased developmental delays, improved cognition and normalized craniofacial anomalies. Therefore, interferon receptor gene dosage determines major hallmarks of Down syndrome, indicating that trisomy 21 elicits an interferonopathy amenable to therapeutic intervention. Correction of interferon receptor gene dosage rescues multiple key phenotypes in a mouse model of trisomy 21.

• Publisher: Cold Spring Harbor Laboratory
• Subject: Genetics